Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 31 2020 - 04:05PM
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in
developing novel, controllable cellular immunotherapies for cancers
and orphan inherited blood disorders, today announced that the
Compensation Committee of the Board of Directors has approved an
inducement award consisting of a stock option to purchase up to
156,000 shares of the Company’s common stock to David E. Strauss.
The stock option was granted on January 31, 2020 with an exercise
price equal to the closing price of the Company’s common stock on
such date. One-fourth of the shares subject to the stock option
will vest on the one-year anniversary of Mr. Strauss’ start date
and the remainder of the shares will vest in a series of 36
successive equal monthly installments thereafter. The stock option
is subject to the terms and conditions of the Company's 2019 Equity
Incentive Plan and a stock option agreement covering the grant.
The stock option was granted as an inducement material to Mr.
Strauss’ entering into employment with the Company in accordance
with Nasdaq Listing Rule 5635(c)(4).
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving
to deliver cures through controllable cell therapies. The company’s
next-generation product candidates are differentiated by powerful
cell signaling technologies designed to produce more effective
CAR-T and allogeneic cell therapies. Bellicum’s lead GoCAR-T®
candidate, BPX-601, is designed to be a more efficacious CAR-T cell
product capable of overriding key immune inhibitory mechanisms.
More information about Bellicum can be found at
www.bellicum.com.
Source: Bellicum Pharmaceuticals
Investors:Robert H. Uhl Managing Director Westwicke IR
858-356-5932 Robert.uhl@westwicke.com
Media: Kate Coyle Senior Vice President Westwicke PR
203-682-8210 kate.coyle@icrinc.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Mar 2023 to Mar 2024